SXTPW — 60 DEGREES PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1946563 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 162,092 | 76,377 | -2,094,961 | -2,089,214 | 6,763,346 | 3,337,760 | 2,018,867 |
| Dec 2025 | 303,385 | 182,703 | -1,917,351 | -1,438,559 | 5,366,211 | 1,510,065 | 1,986,795 |
| Sep 2025 | 437,602 | -100,088 | -2,325,525 | -2,316,324 | 6,689,344 | 4,115,779 | 2,342,386 |
| Jun 2025 | 100,932 | 50,881 | -1,604,828 | -1,733,726 | 4,181,938 | 1,966,930 | 1,836,234 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,993,215
Investing CF
$-254,042
Financing CF
$8,110,544
CapEx
$-254,042
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-49,982,329
Inventory
$910,603
Receivables
$335,836
ST Investments
$0
EBIT TTM
$-7,573,838
Pretax Income TTM
$-7,581,242
Interest Exp TTM
$7,404
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,005,471 | -7,758,579 | -7,365,158 | 5,366,211 | 1,986,795 | — | -6,849,022 |
| Dec 2024 | 607,574 | -9,715,181 | -7,947,107 | 5,759,345 | 1,804,339 | — | -5,648,088 |
| Dec 2023 | 253,573 | -5,154,583 | -3,765,702 | 7,783,771 | 2,985,675 | — | -4,542,910 |
| Dec 2022 | 223,208 | -1,750,445 | -6,181,720 | 1,297,206 | 25,446,266 | — | -1,009,980 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.02T | $1148.84 | — |
| JNJ | JOHNSON & JOHNSON | $617.78B | $256.35 | — |
| ABBV | AbbVie Inc. | $443.36B | $250.94 | — |
| MRK | Merck & Co., Inc. | $321.57B | $130.20 | — |
| NVSEF | NOVARTIS AG | $301.30B | $158.52 | — |
News headlines (Yahoo Finance, 1h cache)
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
2026-07-30 18:23 · Yahoo
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
2026-07-29 20:03 · Yahoo
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
2026-07-08 12:01 · Yahoo
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
2026-07-01 12:02 · Yahoo
60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
2026-06-11 12:03 · Yahoo
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
2026-05-26 12:02 · Yahoo
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
2026-05-15 12:42 · Yahoo
RedChip's Biotech Investor Conference Replays Now Available
2026-04-20 12:00 · Yahoo
60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website
2026-04-15 12:02 · Yahoo
60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know
2026-04-03 16:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.